{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:24:26Z","timestamp":1732857866928,"version":"3.30.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10528-024-10676-x","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T09:03:25Z","timestamp":1708074205000},"page":"4804-4816","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India"],"prefix":"10.1007","volume":"62","author":[{"given":"Gautam","family":"Hazarika","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manash Jyoti","family":"Kalita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha Pratim","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simanta","family":"Kalita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpajit","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipika","family":"Lahkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjanjyoti","family":"Rajkonwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Ghaznavi","family":"Idris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinotsale","family":"Khamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giriraj","family":"Kusre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash","family":"Medhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"issue":"6","key":"10676_CR1","doi-asserted-by":"publisher","first-page":"e0007880","DOI":"10.1371\/journal.pntd.0007880","volume":"14","author":"MTS Al-Ouqaili","year":"2020","unstructured":"Al-Ouqaili MTS, Majeed YH, Al-Ani SK (2020) SEN virus genotype H distribution in \u03b2-thalassemic patients and in healthy donors in Iraq: molecular and physiological study. PLoS Negl Trop Dis 14(6):e0007880. https:\/\/doi.org\/10.1371\/journal.pntd.0007880","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10676_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1179\/1607845413Y.0000000081","volume":"19","author":"S Annamaneni","year":"2014","unstructured":"Annamaneni S, Kagita S, Gorre M, Digumarti RR, Satti V, Battini MR (2014) Methylation status of CEBPA gene promoter in chronic myeloid leukemia. Hematology 19(1):42\u201344. https:\/\/doi.org\/10.1179\/1607845413Y.0000000081","journal-title":"Hematology"},{"issue":"7","key":"10676_CR3","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)\u2013based mutagenesis screen: high efficacy of drug combinations. Blood 108(7):2332\u20132338. https:\/\/doi.org\/10.1182\/blood-2006-02-004580","journal-title":"Blood"},{"issue":"11","key":"10676_CR4","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin AS, Ros\u00e9e PL, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101(11):4611\u20134614. https:\/\/doi.org\/10.1182\/blood-2002-12-3659","journal-title":"Blood"},{"key":"10676_CR5","doi-asserted-by":"publisher","DOI":"10.33590\/emjoncol\/10311536","author":"H de Lavallade","year":"2016","unstructured":"de Lavallade H, Kizilors A (2016) The importance of mutational analysis in chronic myeloid leukaemia for treatment choice. EMJ Oncol. https:\/\/doi.org\/10.33590\/emjoncol\/10311536","journal-title":"EMJ Oncol"},{"key":"10676_CR6","unstructured":"Eden RE, Coviello JM (2023) Chronic myelogenous leukemia."},{"issue":"2","key":"10676_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cncr.26225","volume":"118","author":"DL Gibbons","year":"2012","unstructured":"Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quint\u00e1s-Cardama A (2012) The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 118(2):293\u2013299. https:\/\/doi.org\/10.1002\/cncr.26225","journal-title":"Cancer"},{"issue":"S01","key":"10676_CR8","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.4103\/ijmpo.ijmpo_141_17","volume":"40","author":"M Gorre","year":"2021","unstructured":"Gorre M, Sashidhar R, Annamaneni S, Digumarti R, Satti V (2021) Demographic and clinical characteristics of chronic myeloid leukemia patients: a study on confined populations of Southern India. Indian J. Med Paediatric Oncol 40(S01):S70\u2013S76. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_141_17","journal-title":"Indian J. Med Paediatric Oncol"},{"issue":"1","key":"10676_CR9","first-page":"13","volume":"12","author":"G Hazarika","year":"2023","unstructured":"Hazarika G, Rajkonwar A, Kalita MJ, Kalita S, Das PP, Dutta K, Idris MG, Khamo V, Giriraj K, Medhi S (2023) Association of BCR-ABL transcript variants with different blood parameters and demographic characteristics of chronic myeloid leukemia patients in a tertiary care center of North-East India. Int J Sci Res Rev 12(1):13\u201331","journal-title":"Int J Sci Res Rev"},{"issue":"18","key":"10676_CR10","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","volume":"121","author":"A Hochhaus","year":"2013","unstructured":"Hochhaus A, Saglio G, Larson RA, Kim D-W, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP (2013) Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 121(18):3703\u20133708. https:\/\/doi.org\/10.1182\/blood-2012-04-423418","journal-title":"Blood"},{"issue":"32","key":"10676_CR11","doi-asserted-by":"publisher","first-page":"19221","DOI":"10.1073\/pnas.1919221117","volume":"117","author":"M Hoemberger","year":"2020","unstructured":"Hoemberger M, Pitsawong W, Kern D (2020) Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proc Natl Acad Sci 117(32):19221\u201319227. https:\/\/doi.org\/10.1073\/pnas.1919221117","journal-title":"Proc Natl Acad Sci"},{"issue":"25","key":"10676_CR12","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, M\u00fcller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 27(25):4204\u20134210. https:\/\/doi.org\/10.1200\/JCO.2009.21.8230","journal-title":"J Clin Oncol"},{"issue":"10","key":"10676_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O\u2019Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767\u20131773. https:\/\/doi.org\/10.1038\/sj.leu.2404318","journal-title":"Leukemia"},{"key":"10676_CR14","doi-asserted-by":"publisher","DOI":"10.5339\/jemtac.2022.aimco.8","author":"BA Kanaan","year":"2022","unstructured":"Kanaan BA, Al-Ouqaili MTS, Murshed RM (2022) In terms of the PCR-RFLP technique, genetic screening of Ala575Val inactivating mutation in patients with amenorrhea. J Emergency Med Trauma Acute Care. https:\/\/doi.org\/10.5339\/jemtac.2022.aimco.8","journal-title":"J Emergency Med Trauma Acute Care"},{"issue":"2","key":"10676_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ol.2020.11650","volume":"20","author":"J Liu","year":"2020","unstructured":"Liu J, Yang H, Xu X, Yi S, Meng L (2020) Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis. Oncol Lett 20(2):1071\u20131076. https:\/\/doi.org\/10.3892\/ol.2020.11650","journal-title":"Oncol Lett"},{"issue":"2","key":"10676_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10585-021-10144-5","volume":"39","author":"AL Parker","year":"2022","unstructured":"Parker AL, Benguigui M, Fornetti J, Goddard E, Lucotti S, Insua-Rodr\u00edguez J, Wiegmans AP (2022) Current challenges in metastasis research and future innovation for clinical translation. Clin Exp Metas 39(2):263\u2013277. https:\/\/doi.org\/10.1007\/s10585-021-10144-5","journal-title":"Clin Exp Metas"},{"key":"10676_CR17","doi-asserted-by":"publisher","DOI":"10.17795\/ijcp2334","author":"L Rejali","year":"2015","unstructured":"Rejali L, Poopak B, Hasanzad M, Sheikhsofla F, Varnoosfaderani AS, Safari N, Rabieipoor S (2015) Characterizing of four common BCR-ABL kinase domain mutations (T315I, Y253H, M351T and E255K) in Iranian chronic myelogenous leukemia patients with imatinib resistance. Iran J Cancer Prev. https:\/\/doi.org\/10.17795\/ijcp2334","journal-title":"Iran J Cancer Prev"},{"issue":"3","key":"10676_CR18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai J-L, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100(3):1014\u20131018. https:\/\/doi.org\/10.1182\/blood.V100.3.1014","journal-title":"Blood"},{"issue":"7","key":"10676_CR19","first-page":"3109","volume":"11","author":"A Saini","year":"2020","unstructured":"Saini A, Kumar M, Bhatt S, Saini V, Malik A (2020) Cancer causes and treatments. Int J Pharm Sci Res 11(7):3109\u20133122","journal-title":"Int J Pharm Sci Res"},{"issue":"2","key":"10676_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117\u2013125. https:\/\/doi.org\/10.1016\/S1535-6108(02)00096-X","journal-title":"Cancer Cell"},{"issue":"8","key":"10676_CR21","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1128\/AAC.48.8.2787-2792.2004","volume":"48","author":"SL Spruance","year":"2004","unstructured":"Spruance SL, Reid JE, Grace M, Samore M (2004) hazard ratio in clinical trials. Antimicrob Agents Chemother 48(8):2787\u20132792. https:\/\/doi.org\/10.1128\/AAC.48.8.2787-2792.2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"03","key":"10676_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/0971-5851.123748","volume":"34","author":"S Srivastava","year":"2013","unstructured":"Srivastava S, Dutt S (2013) Imatinib mesylate resistance and mutations: an Indian experience. Indian J Med Paediatric Oncol 34(03):213\u2013220. https:\/\/doi.org\/10.4103\/0971-5851.123748","journal-title":"Indian J Med Paediatric Oncol"},{"issue":"3","key":"10676_CR23","first-page":"134","volume":"41","author":"T Styles","year":"2016","unstructured":"Styles T, Wu M, Wilson R, Babcock F, Butterworth D, West DW, Richardson LC (2016) Population-based testing and treatment characteristics for chronic myelogenous leukemia. J Registry Manag 41(3):134\u2013142","journal-title":"J Registry Manag"},{"issue":"1","key":"10676_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-9966-29-54","volume":"29","author":"Y Wang","year":"2010","unstructured":"Wang Y, Qian J, Lin J, Yao D, Qian Z, Zhu Z, Li J (2010) Methylation status of DDIT3 gene in chronic myeloid leukemia. J Exp Clin Cancer Res 29(1):54. https:\/\/doi.org\/10.1186\/1756-9966-29-54","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"10676_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00277-006-0171-8","volume":"85","author":"Y Wei","year":"2006","unstructured":"Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H (2006) Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Ann Hematol 85(12):841\u2013847. https:\/\/doi.org\/10.1007\/s00277-006-0171-8","journal-title":"Ann Hematol"},{"issue":"3","key":"10676_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hern\u00e1ndez-Boluda J-C et al (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26(3):428\u2013442. https:\/\/doi.org\/10.1016\/j.ccr.2014.07.006","journal-title":"Cancer Cell"},{"issue":"18","key":"10676_CR27","doi-asserted-by":"publisher","first-page":"e25579","DOI":"10.1097\/MD.0000000000025579","volume":"100","author":"M Zhao","year":"2021","unstructured":"Zhao M, Gui X, Wu Q, Xia L, Wang Y (2021) The role of E255K\/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies. Medicine 100(18):e25579. https:\/\/doi.org\/10.1097\/MD.0000000000025579","journal-title":"Medicine"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-024-10676-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10528-024-10676-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-024-10676-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:10:48Z","timestamp":1732803048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10528-024-10676-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10676"],"URL":"https:\/\/doi.org\/10.1007\/s10528-024-10676-x","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"type":"print","value":"0006-2928"},{"type":"electronic","value":"1573-4927"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Ethics Committee of Assam Medical College Hospital, Dibrugarh, Assam No AMC\/EC\/1594 dated 24\/7\/2020 and Gauhati University Ethics Committee, Guwahati, Assam No: GUIEC\/2021\/019 dated: 29\/9\/2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Before taking the blood sample, all the participants of the study (Case\/Patients) voluntarily gave their consent for the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors have given consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}